News

United Therapeutics and Corsair to Work Together on Skin Patch to Deliver Pulmonary Hypertension Therapy

United Therapeutics and Corsair Pharma are teaming up to advance Corsair’s development of a blood-vessel-widening skin patch for treating pulmonary arterial hypertension. The patch will contain treprostinil, which is already available in other forms. Both companies have been working on ways to improve the administration of the compound. United developed a…

Multi-category Index Can Predict Adempas-treated PAH Patients’ Outcomes, Study Finds

Using a multi-category index to assess pulmonary hypertension patients’ response to Adempas (riociguat) can help doctors predict their survival, a study reports. REVEAL risk scores can also help doctors predict patients’ progression-free survival — or the length of time it takes for their disease to worsen, researchers said. The study, which…

Bellerophon Enrolls First Patient in Phase 2b Trial of INOpulse as Treatment for ILD-linked PH

Bellerophon Therapeutics has enrolled the first patient in a Phase 2b clinical trial evaluating INOpulse as a treatment for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The trial (NCT03267108) will assess the safety and effectiveness of Bellerophon’s pulsed, inhaled nitric oxide treatment for people with PH-ILD, including…

Top 10 Pulmonary Hypertension Articles of 2017

Important research findings, therapy advances, and other events related to pulmonary hypertension were reported daily in Pulmonary Hypertension News during 2017. Now that the year is over, it’s time to briefly review the articles that appealed most to our readers. Here are the Top 10 most-read articles of 2017, with a brief description of…

Phase 1 Trial for Camurus’ Long-acting CAM2043 Gets Underway

The first healthy participants have been injected with CAM2043 (treprostinil FluidCrystal Injection Depot) in a Phase 1 study assessing the treatment’s safety, tolerability, and pharmacokinetics in both single and repeated doses, the Swedish pharmaceutical company Camurus announced. CAM2043 contains treprostinil, a therapy that is effective for treating pulmonary…